| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alzamend Neuro, Inc. (ALZN) has 3 insiders with recent SEC Form 4 filings, including 14 buys and 0 sells. ALZN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 25 | $26.00 | - | |
| Dir | 0 | - | - | |
| Dir | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Jackman Stephan | Chief Executive Officer | Buy | 37,000 | $0.54 | $19,998.50 | +435.3% | -14.1% | -91.2% | |
| Mar 22, 2023 | McGrath Lynne Fahey | Director | Buy | 10,000 | $0.44 | $4,350.00 | New | +57.7% | -84.0% | |
| Mar 17, 2023 | Ault Milton C III | 10% Owner | Buy | 9,000 | $0.46 | $4,154.60 | - | +70.0% | -84.5% | |
| Feb 15, 2023 | Ault Milton C III | 10% Owner | Buy | 1,000 | $0.60 | $597.30 | - | -9.6% | -90.0% | |
| Dec 28, 2022 | Ault Milton C III | 10% Owner | Buy | 4,000 | $0.57 | $2,276.89 | - | -17.9% | -88.8% | |
| Dec 21, 2022 | Ault Milton C III | 10% Owner | Buy | 5,000 | $0.81 | $4,049.50 | - | -45.1% | -92.2% | |
| Dec 19, 2022 | Ault Milton C III | 10% Owner | Buy | 43,000 | $0.86 | $36,773.20 | +0.4% | -55.6% | -92.3% | |
| Nov 18, 2022 | Ault Milton C III | 10% Owner | Buy | 1,000 | $1.29 | $1,289.00 | - | -54.4% | -91.0% | |
| Nov 2, 2022 | Ault Milton C III | 10% Owner | Buy | 1,000 | $1.13 | $1,129.90 | - | -39.7% | -90.0% | |
| Oct 31, 2022 | Ault Milton C III | 10% Owner | Buy | 6,000 | $1.19 | $7,135.80 | - | -43.5% | -90.0% |